The breakpoint cluster region site in patients with Philadelphia chromosome–positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations
✍ Scribed by Claire F. Verschraegen; Hagop M. Kantarjian; Cherryl Hirsch-Ginsberg; Ming S. Lee; Susan O'Brien; Mary B. Rios; Sandford A. Stass; Michael Keating; Moshe Talpaz
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 608 KB
- Volume
- 76
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Background. Five to 10% of patients with chronic myelogenous leukemia (CML) do not have the Philadelphia chromosome (Ph), but one-third of them have rearrangements of the breakpoint cluster region (BCR-positive). Methods. The authors analyzed the characteristics, treatment response, and prognosis o
## Background: Patients with chronic myelogenous leukemia (cml) occasionally experience persistent thrombocythemia despite having adequate white blood cell (wbc) counts. trimethylenethiophosphoramide (thiotepa) is an alkylating agent that significantly inhibits platelet production. ## Methods: Th
We report the sublocalization of the breakpoint in chromosome 22 in 33 patients with chronic myeloid leukemia (CML) who also had unusual marrow cytogenetics. In 23 patients, the leukemic clones were characterized by Philadelphia (Ph') chromosomes that arose through complex translocations that involv